DataMeds AI, Inc.
corporate_fare Company Profile
DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for MEDS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for MEDS spans 8-K, PRE 14C, 10-Q, S-1.
Recent high-impact activity:
- Corexa Pharmacy Tops $1M Monthly Revenue, Up 66% Since July
- DataMeds AI Settles Litigation, Wipes Out $19M in Liabilities
- DataMeds AI Settles MIPA Litigation, Extinguishes ~$19M Liability for $450K
- DataMeds Acquires Helomics for $1.5M in Stock and Convertible Note with Full-Ratchet Anti-Dilution
- DataMEDS Acquires Helomics AI Cancer Diagnostics Lab for $1.5M
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 430,628 shares in MEDS as of the September 15, 2026 settlement, a 147.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 57.8% of MEDS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MEDS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-31.
Blank Check Preferred Stock Authorized · Series A Preferred Stock Terms Revealed
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →